Related posts: BRIEF-Regeneron and Sanofi announce positive Dupilumab topline results from two Phase 3 trials in inadequately controlled moderate-to-severe atopic Dermatitis patients UPDATE 2-Fed’s Dudley sees risks lingering, cautious on U.S. rate hikes Selfies in the Voting Booth? Snapchat Fights for the Right. Auditors rebuke UN development agency after U.S. indictments Post navigation Japanese parties contort as tax-hike delay grows likely BRIEF-Trovagene files for mixed shelf of up to $250 million
